poisar

Stock

TScan Therapeutics, Inc. TCRX

$0.76-2.74%

Overview

TCRX market data

Price History

TCRX price chart · 1M
O
0.777700
H
0.777900
L
0.747500
C
0.756000
Vol
9,058.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$0.78
Previous Close
$0.78
Day High
$0.78
Day Low
$0.75
52 Week High
$1.34
52 Week Low
$0.72
7 Day Return
-2.98%
30 Day Return
-1.83%
90 Day Return
-30.32%
1 Year Return
-34.55%
Daily Notional Volume
$6.8K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.00
Diluted earnings per share over the trailing twelve months.
Beta
1.14
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,360.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.72 – $2.57
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $50.5M · P/B 0.46 · P/S 5.52.

Company News

10 captured
12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · Aug 19, 2026, 9:05 PM
Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026Benzinga · Aug 18, 2026, 9:08 PM
8-K filing — TScan Therapeutics, Inc. (TCRX)SEC EDGAR · Aug 18, 2026, 9:00 PM
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price TargetBenzinga · Aug 12, 2026, 3:25 PM
TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M EstimateBenzinga · Aug 12, 2026, 11:10 AM
TScan Therapeutics Announces First Patient Infused With TSC-101 In Pivotal Phase 3 ALLOHA-2 Trial For AML, MDS Relapse Prevention After TransplantBenzinga · Jul 29, 2026, 11:06 AM
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price TargetBenzinga · Jun 23, 2026, 12:25 PM
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price TargetBenzinga · Jun 23, 2026, 11:50 AM
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationGlobenewswire Inc · Jun 22, 2026, 11:15 AM
TScan Says Cancer Therapy Data Support Move to Phase 3 TrialBenzinga · Jun 22, 2026, 11:10 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
TScan Therapeutics, Inc. (TCRX) stock — price, valuation & news | Poisar